Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy

Among patients with advanced‐stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET‐2) has prognostic value. However, 15% of patients with a negative PET‐2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation‐regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET‐driven trial...